Baseline characteristics of patients
| Original sample | Evaluation sample | |||
|---|---|---|---|---|
| Anti-TNF | nbDMARD | Anti-TNF | nbDMARD | |
| N | 3271 | 1773 | 1522 | 1468 |
| Female, n (%) | 2556 (78.1) | 1394 (78.6) | 1143 (75.1%) | 1106 (75.3%) |
| Age | 53.8 (12.3) | 56.2 (11.5) | 55.8 (12.9) | 58.2 (12.5) |
| Disease duration (years), median (IQR) | 9 (5, 16) | 6 (3, 12) | 7 (3, 14) | 4 (2, 9) |
| Follow-up time (years), median (IQR) | 3.1 (2.1, 4.9) | 3.3 (2.5, 5.0) | 1.5 (0.6, 2.1) | 1.6 (0.9, 2.4) |
| Rheumatoid factor positive, n (%) | 2624 (80.2) | 1271 (71.7) | 1095 (72.8) | 866 (59.0) |
| DAS28 | 5.7 (1.2) | 5.1 (1.3) | 5.1 (1.3) | 4.6 (1.3) |
| FFbH | 57.0 (23.0) | 66.6 (21.5) | 64.8 (22.8) | 71.2 (21.8) |
| Smoking never, n (%) | 1027 (47.0) | 585 (45.6) | 667 (44.5) | 693 (48.0) |
| No. of previous DMARDs | 3.3 (1.3) | 1.8 (1.0) | 2.5 (1.1) | 1.6 (0.9) |
| No. of previous biologicals | 0.23 (0.6) | 0.01 (0.1) | 0.24 (0.57) | 0.07 (0.34) |
| Glucocorticoids 7.5–14 mg/day, n (%) | 1027 (31.4) | 386 (21.8) | 383 (25.2) | 171 (11.6) |
| Glucocorticoids ≥15 mg/day, n (%) | 491 (15.0) | 147 (8.3) | 117 (7.7) | 50 (3.4) |
| Chronic lung disease, n (%) | 246 (7.5) | 112 (6.3) | 111 (7.3) | 88 (6.0) |
| Chronic renal disease, n (%) | 139 (4.3) | 31 (1.8) | 57 (3.8) | 27 (1.8) |
Values are means and SDs if not otherwise specified.
; nbDMARD, non-biological disease-modifying antirheumatic drug; TNF, tumour necrosis factor.